 |
|
|
| |
New Drugs and Strategies for the Treatment of HIV
|
| |
| |
Reported by Jules Levin
Glasgow HIV Oct 27-31 2018
Review Includes review of new HIV drugs in development and recently approved and going research for treatment naives and heavily treatment=experienced.
Download the PDF here
"there is a rich HIV pipeline to help those patients harbouring multidrug-resistant viruses.....new drugs or compounds, together with new delivery pathways, are likely to improve treatment satisfaction, quality of life and, most of all, choices, similar to contraception, where long-acting reversible contraception is more efficient compared to the daily intake of pills....Cabotegravir and rilpivirine in long-acting formulations may be the pioneer of new administration routes. Injections, but also implants, made possible for molecules such as the new potent MK 8591, child-adapted granules, or a vaginal ring developed for prevention, all have the potential to revolutionize ART delivery with the aim to reach the the patients beyond the 90 targets.....Patients with MDR viruses: Ibalizumab, Fostemsavir, MK-8591, GS-9131, mABs; to design newclinic studies: Solliciting feedback from patients and investigator sites....the antiretroviral agents catalyzed drug discovery for other viral diseases......dual therapy.....The clinical response to depression suffers from a treatment cascade: of prevalent cases 47% are recognized.....Despite the lack of comparison with tenofovir alafenamide-based 3-drug regimens, the 2-drug regimens showing consistent non-inferiority and safety versus 3-drug regimens will challenge the current paradigm of 3-drug ART"
talk pdf attached
Glasgow Plenary
Alxandra Calmy, MD, PhD
In conclusion, 2018 is an important year for HIV research. Newer drugs with new mechanisms of action and (child-adapted) formulations will meet the need for improved regimens. Reaching the remaining 10-10-10 will require major efforts from all stakeholders, including clinical researchers. Options for heavily pre-treated patients are becoming a reality and a menu of options may be beneficial to achieve a patient-centred approach (similar to contraception).
Despite the tremendous burden of HIV disease worldwide over the past decades, the heightened awareness of the disease has also brought positive benefits in its wake. Today, the challenge is to achieve in other health fields what made HIV a success story: civil society engagement, resource mobilization, innovation and research, and a focus on impact.
|
| |
|
|
|
|
|
